Campbell & CO Investment Adviser LLC
Position in ENTA — Enanta Pharmaceuticals Inc
CIK 1353570
BALTIMORE, MD
Position in ENTA
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$1,031,739
+$523,837 QoQ
Shares Held
70,764
+76.0% QoQ
Ownership
0.243%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
#35
of 122 holders
Holding Since
Dec 2021
6 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ENTA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Campbell & CO Investment Adviser LLC holds $71,968,852 across 46 Biotechnology names. ENTA ranks #22 (1.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
9,899 | $6,172,422 | |
| 2 | CRSP |
CRISPR Therapeutics AG
|
107,529 | $5,864,631 | |
| 3 | CYTK |
Cytokinetics Inc
|
65,978 | $5,620,665 | |
| 4 | INSM |
INSMED Inc
|
43,856 | $4,675,926 | |
| 5 | IONS |
Ionis Pharmaceuticals Inc
|
49,632 | $3,935,321 | |
| 6 | HALO |
Halozyme Therapeutics, Inc.
|
44,702 | $3,498,825 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
11,183 | $3,366,418 | |
| 8 | RPRX |
Royalty Pharma plc
|
52,688 | $2,954,216 |
All Filings in ENTA
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,031,739 | 70,764 | Shares | Sole | 2026-08-03 | |
| 2026-03-31 | $507,902 | 40,214 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $853,929 | 54,149 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $225,694 | 18,855 | Shares | Sole | 2025-10-28 | |
| 2022-09-30 | $674,621 | 13,006 | Shares | Sole | 2022-11-14 | |
| 2021-12-31 | $269,208 | 3,600 | Shares | Sole | 2022-02-10 | |
| No filing history on record for this holder in this stock. | ||||||